Copyright
©The Author(s) 2022.
World J Crit Care Med. Jan 9, 2022; 11(1): 48-57
Published online Jan 9, 2022. doi: 10.5492/wjccm.v11.i1.48
Published online Jan 9, 2022. doi: 10.5492/wjccm.v11.i1.48
Table 1 Baseline characteristics of study population
| Remdesivir (n = 20) | Control (n = 25) | |
| Mean age (yr) | 64.20 (± 15.16) | 68.32 (± 12.67) |
| Age groups in years (n, %) | ||
| 18-40 | 2 (10) | 1 (4) |
| 41-64 | 5 (25) | 7 (28) |
| Above 65 | 13 (65) | 17 (68) |
| Females (n, %) | 11 (55) | 12 (48) |
| Race or ethnic group (n, %) | ||
| White or Caucasian | 9 (45) | 12 (48) |
| Hispanic | 5 (25) | 9 (36) |
| Black or African American | 2 (10) | 2 (8) |
| Other | 4 (20) | 2 (8) |
| Tobacco use (n, %) | 11 (55) | 14 (56) |
| Diabetes mellitus (n, %) | 13 (65) | 20 (80) |
| Hypertension (n, %) | 19 (95) | 24 (96) |
| Coronary artery disease/peripheral vascular disease (n, %) | 8 (40) | 9 (36) |
| Congestive heart failure (n, %) | 10 (50) | 12 (48) |
| History of lung disease- no. (%) | 6 (30) | 9 (36) |
| Obesity (BMI>30 kg/m2) (n, %) | 8 (40) | 12 (48) |
| Arrhythmia (n, %) | 6 (30) | 9 (36) |
| Length of stay - d (± SD) | 13.00 (± 7.35) | 12.16 (± 8.38) |
| Treatment (n, %) | ||
| Corticosteroids | 20 (100) | 17 (68) |
| Antibiotics | 13 (65) | 13 (52) |
| Therapeutic anticoagulation | 9 (45) | 11 (44) |
- Citation: Selvaraj V, Lal A, Finn A, Tanzer JR, Baig M, Jindal A, Dapaah-Afriyie K, Bayliss G. Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease. World J Crit Care Med 2022; 11(1): 48-57
- URL: https://www.wjgnet.com/2220-3141/full/v11/i1/48.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v11.i1.48